Rafael Holdings, Inc.
RFLNYSEHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $30,000 | $637,000 | $279,000 | $410,000 | $802,000 | $4.9M |
| Operating income | −$29.2M | −$102.6M | −$15.0M | −$60.5M | −$28.2M | −$8.5M |
| Net income | −$30.5M | −$34.4M | −$1.9M | −$124.7M | −$23.1M | −$10.8M |
| Total assets | $114.1M | $96.8M | $98.8M | $118.3M | $154.1M | $136.3M |
| Total liabilities | $15.7M | $10.6M | $2.2M | $21.1M | $17.4M | $5.8M |
| Equity | $94.4M | $82.2M | $100.3M | $100.5M | $122.3M | $116.8M |
| EPS (diluted) | $-1.04 | $-1.45 | $-0.08 | $-6.31 | $-1.49 | — |
| Shares out. | 29.4M | 23.7M | 23.3M | 19.8M | 16.5M | — |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −97196.7%
- Net margin
- −101733.3%
- Return on equity
- −32.3%
- Return on assets
- −26.7%
- Return on capital (ROCE)
- −28.4%
- Liabilities / assets
- 13.8%
- Debt / equity
- 0.17×
- Book value / share
- $3.21
- Revenue growth (YoY)
- −95.3%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 0.54distress
- Accruals / assets
- −10.2%clean
- Piotroski F-Score
- 2/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 4 warning● 2 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Oct 30, 2024
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Jonas Howard SActivist (13D)Jun 9, 2025
- I9 Plus, LlcActivist (13D)Jun 9, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 54,609 | 1.0 | +24.0% |
| Apr 30, 2026 | 44,054 | 1.0 | +37.3% |
| Apr 15, 2026 | 32,087 | 1.0 | -5.5% |
| Mar 31, 2026 | 33,970 | 1.0 | -15.1% |
| Mar 13, 2026 | 40,019 | 1.0 | -27.5% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Regulation FD disclosure · Other material eventApr 22, 2026
- Results of operationsMar 16, 2026
- Shareholder voteJan 12, 2026
- Results of operationsDec 11, 2025
- Other material eventDec 2, 2025
- Results of operationsOct 29, 2025
- Director / officer changeOct 28, 2025
- Regulation FD disclosureOct 10, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 8-KCURRENT REPORTApr 22, 2026
- 4Mar 24, 2026
- 4Mar 17, 2026
- 10-QQUARTERLY REPORTMar 16, 2026
- 8-KCURRENT REPORTMar 16, 2026
- 4Jan 30, 2026
- 4Jan 29, 2026
- 4Jan 29, 2026
- 4Jan 29, 2026
- S-8REGISTRATION STATEMENTJan 27, 2026
- 4Jan 15, 2026
- 4Jan 15, 2026
- 8-KCURRENT REPORTJan 12, 2026
- 4Dec 23, 2025
- 4Dec 16, 2025
Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.